A Phase Ib/II Study of AK112 (PD-1/VEGF Bispecific Antibody) in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC).

This document provides information about a clinical trial, with the identifier NCT06530251, that is currently being conducted in China. The trial aims to evaluate the safety and effectiveness of AK112, a PD-1/VEGF bispecific antibody, in combination therapy for patients with advanced hepatocellular carcinoma (HCC), a type of liver cancer. The trial consists of two parts: a phase Ib trial to determine the maximum tolerable dose and recommended phase 2 dose of AK112, and a phase II trial to compare the safety and efficacy of AK112 in combination therapy or monotherapy with other drug combinations. The trial is expected to be completed by June 2026 and aims to enroll 280 participants who have not received previous anti-tumor treatment. [Extracted from the article]